Med BioGene Inc
Many Bright Ideas Technologies Inc. does not have significant operations. Previously, the company was involved in the life science business with a focus on the commercialization of prognostic genomic-based tests for non-small-cell lung cancer. It focuses on the commercialization of technologies in various industrial sectors. Many Bright Ideas Technologies Inc. is headquartered in Vancouver, Canad… Read more
Med BioGene Inc (MBGNF) - Net Assets
Latest net assets as of September 2025: $-211.92K USD
Based on the latest financial reports, Med BioGene Inc (MBGNF) has net assets worth $-211.92K USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($5.78K) and total liabilities ($217.70K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-211.92K |
| % of Total Assets | -3663.85% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 235.88 |
Med BioGene Inc - Net Assets Trend (2004–2024)
This chart illustrates how Med BioGene Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Med BioGene Inc (2004–2024)
The table below shows the annual net assets of Med BioGene Inc from 2004 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-168.53K | -32.72% |
| 2023-12-31 | $-126.98K | -91.72% |
| 2022-12-31 | $-66.23K | +18.45% |
| 2021-12-31 | $-81.22K | +15.69% |
| 2020-12-31 | $-96.34K | -158.50% |
| 2019-12-31 | $-37.27K | +72.15% |
| 2018-12-31 | $-133.82K | -49.90% |
| 2017-12-31 | $-89.27K | -1771.45% |
| 2016-12-31 | $-4.77K | +92.08% |
| 2015-12-31 | $-60.22K | -57.25% |
| 2014-12-31 | $-38.30K | -134.00% |
| 2013-12-31 | $112.62K | -61.78% |
| 2012-12-31 | $294.65K | -47.05% |
| 2011-12-31 | $556.45K | +137.23% |
| 2010-12-31 | $-1.49 Million | -219.54% |
| 2009-12-31 | $1.25 Million | +47.00% |
| 2008-12-31 | $850.68K | -47.52% |
| 2007-12-31 | $1.62 Million | +560.53% |
| 2006-12-31 | $245.40K | +137.19% |
| 2005-12-31 | $-659.88K | -91.58% |
| 2004-12-31 | $-344.44K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Med BioGene Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1434341693.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $9.28 Million | % |
| Other Comprehensive Income | $310.02K | % |
| Other Components | $5.07 Million | % |
| Total Equity | $-168.53K | 100.00% |
Med BioGene Inc Competitors by Market Cap
The table below lists competitors of Med BioGene Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Neuberger Berman IMF Inc
NYSE MKT:NBH
|
$94.37K |
|
Aditxt Inc.
NASDAQ:ADTX
|
$94.39K |
|
ENSPF
PINK:ENSPF
|
$94.46K |
|
BlackRock Long-Term Municipal Advantage Trust
NYSE:BTA
|
$94.48K |
|
PMFAX
NMFQS:PMFAX
|
$94.27K |
|
Seoyonehwa
KQ:200880
|
$94.27K |
|
Porto Aviation Group S.p.A.
F:M2N
|
$94.22K |
|
A.G.Barr PLC
LSE:BAG
|
$94.20K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Med BioGene Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -126,985 to -168,533, a change of -41,548.
- Net loss of 51,515 reduced equity.
- Other comprehensive income increased equity by 12,566.
- Other factors decreased equity by 2,599.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-51.52K | -30.57% |
| Other Comprehensive Income | $12.57K | +7.46% |
| Other Changes | $-2.60K | -1.54% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Med BioGene Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-12-31 | $-0.43 | $0.01 | x |
| 2005-12-31 | $-0.76 | $0.01 | x |
| 2006-12-31 | $0.14 | $0.01 | x |
| 2007-12-31 | $0.63 | $0.01 | x |
| 2008-12-31 | $0.25 | $0.01 | x |
| 2009-12-31 | $0.23 | $0.01 | x |
| 2010-12-31 | $-0.20 | $0.01 | x |
| 2011-12-31 | $0.07 | $0.01 | x |
| 2012-12-31 | $0.04 | $0.01 | x |
| 2013-12-31 | $0.01 | $0.01 | x |
| 2014-12-31 | $0.00 | $0.01 | x |
| 2015-12-31 | $-0.01 | $0.01 | x |
| 2016-12-31 | $0.00 | $0.01 | x |
| 2017-12-31 | $-0.01 | $0.01 | x |
| 2018-12-31 | $-0.02 | $0.01 | x |
| 2019-12-31 | $0.00 | $0.01 | x |
| 2020-12-31 | $-0.01 | $0.01 | x |
| 2021-12-31 | $-0.01 | $0.01 | x |
| 2022-12-31 | $0.00 | $0.01 | x |
| 2023-12-31 | $-0.01 | $0.01 | x |
| 2024-12-31 | $-0.01 | $0.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Med BioGene Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-110.04%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | 0.00% | -2388.48% | 0.10x | 0.00x | $-323.18K |
| 2005 | 0.00% | -2647.87% | 0.18x | 0.00x | $-703.27K |
| 2006 | -1231.87% | 0.00% | 0.00x | 3.11x | $-3.05 Million |
| 2007 | -153.06% | 0.00% | 0.00x | 1.27x | $-2.64 Million |
| 2008 | -215.59% | 0.00% | 0.00x | 1.37x | $-1.92 Million |
| 2009 | -185.70% | 0.00% | 0.00x | 1.74x | $-2.45 Million |
| 2010 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.83 Million |
| 2011 | 274.96% | 66.72% | 2.44x | 1.69x | $1.47 Million |
| 2012 | -125.57% | 0.00% | 0.00x | 1.43x | $-399.47K |
| 2013 | -673.92% | 0.00% | 0.00x | 1.63x | $-770.26K |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-287.17K |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-366.98K |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $23.12K |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-330.14K |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-41.24K |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-59.75K |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-44.91K |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-51.84K |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-56.44K |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-45.41K |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-34.66K |
Industry Comparison
This section compares Med BioGene Inc's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $914,015,556
- Average return on equity (ROE) among peers: -22.24%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Med BioGene Inc (MBGNF) | $-211.92K | 0.00% | N/A | $94.32K |
| Agilent Technologies Inc (A) | $4.08 Billion | 3.46% | 0.65x | $31.80 Billion |
| Amer Bio Medica (ABMC) | $3.38 Million | -26.64% | 1.08x | $3.55K |
| ADCNF (ADCNF) | $1.77 Billion | 2.65% | 1.64x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $1.68 Million |
| ANGLE plc (ANPCF) | $18.44 Million | -77.14% | 0.38x | $34.42 Million |
| SeqLL Inc. (ATLN) | $8.18 Million | -45.26% | 0.31x | $35.63K |
| Avricore Health Inc (AVCRF) | $2.20 Million | -79.50% | 0.04x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $-11.46 Million | 0.00% | 0.00x | $664.47K |
| Biodesix Inc (BDSX) | $-198.03 Million | 0.00% | 0.00x | $50.38 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $5.08 Million |